Failing to make any significant rebound, device financing – which totaled $1.6bn for the first quarter of 2019 – increased only 7% from Q4 2018's $1.5bn aggregate, which was the lowest quarter of last year. The group bringing in the most during Q1 was again (as in Q4 2018) late-stage venture rounds, which accounted for 36% of the total at $566m. Just behind late-stage venture rounds were debt financings, which reached $515m, or 33% of the quarter's dollars. (See Exhibit 1.)
Device/Diagnostics Quarterly Dealmaking Statistics, Q1 2019
A look at the financing, M&A and alliance activity in January–March 2019
Device financing totaled $1.6bn for the first quarter of 2019. Late-stage venture rounds were the most active category, led by Nuvaira's $79m Series E financing. Merger and acquisition activity reached $7.3bn; in the largest transaction of the quarter, Ethicon acquired Auris Health for up to $6bn. Diagnostics/research financing reached $1.7bn, and ten diagnostics/research tools companies were acquired, five of which together were valued at $22.6bn.
More from Deal-Making
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
More from In Vivo
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.